Table of Contents
- What is CLIC-1901 CAR T-Cell Therapy?
- How Does CLIC-1901 CAR T-Cell Therapy Work?
- What Conditions Does CLIC-1901 CAR T-Cell Therapy Target?
- The DAN-CART 1901 Clinical Trial
- Who is Eligible for the CLIC-1901 CAR T-Cell Therapy Trial?
- Safety and Efficacy Measures
- Potential Side Effects
What is CLIC-1901 CAR T-Cell Therapy?
CLIC-1901 CAR T-cell therapy is an innovative treatment being developed for patients with certain types of blood cancers that have not responded well to other treatments or have come back after previous therapies[1]. This therapy belongs to a category of treatments called advanced therapy medicinal products (ATMPs), specifically a type of cell therapy that uses genetically modified cells to fight cancer.
How Does CLIC-1901 CAR T-Cell Therapy Work?
CLIC-1901 CAR T-cell therapy works by using the patient’s own immune cells, specifically T-cells, which are a type of white blood cell. These cells are collected from the patient and then modified in a laboratory using a lentiviral vector, which is a tool that helps introduce new genetic material into the cells[1]. This genetic modification equips the T-cells with a special receptor called a Chimeric Antigen Receptor (CAR) that targets a protein called CD19, which is found on the surface of certain cancer cells.
Once modified, these CAR T-cells are grown in large numbers and then infused back into the patient. The modified cells are designed to recognize and attack cancer cells that have the CD19 protein, potentially providing a powerful and targeted treatment for certain blood cancers.
What Conditions Does CLIC-1901 CAR T-Cell Therapy Target?
CLIC-1901 CAR T-cell therapy is being developed to treat several types of blood cancers that express the CD19 protein. These include[1]:
- Acute Lymphoblastic Leukemia (ALL): A fast-growing cancer of lymphocyte-producing cells in the bone marrow
- B-cell Non-Hodgkin Lymphoma (NHL): A group of blood cancers that develop from lymphocytes (a type of white blood cell)
- Diffuse Large B-cell Lymphoma (DLBCL): The most common type of non-Hodgkin lymphoma
- Burkitt Lymphoma: A rare but aggressive form of NHL
- Primary Mediastinal Large B-cell Lymphoma: A subtype of DLBCL that typically occurs in young adults
- Mantle Cell Lymphoma: A rare type of B-cell NHL
- Transformed Follicular Lymphoma: When a slow-growing lymphoma changes into a more aggressive form
- Richter-transformed Chronic Lymphocytic Leukemia (CLL): When CLL transforms into an aggressive lymphoma
The DAN-CART 1901 Clinical Trial
A clinical trial called DAN-CART 1901 is currently underway to test the safety and effectiveness of CLIC-1901 CAR T-cell therapy[1]. This is a Phase II-III trial, which means it’s in a later stage of testing where researchers are looking closely at how well the treatment works and any side effects it might cause.
The main goals of this trial are:
- To test the safety and feasibility of using CLIC-1901 CAR T-cells in patients with relapsed or refractory CD19-expressing blood cancers
- To evaluate how effective the treatment is in fighting these cancers
- To analyze factors that might contribute to the treatment not working in some cases
- To study biological and immunological markers during the treatment
Who is Eligible for the CLIC-1901 CAR T-Cell Therapy Trial?
The trial is open to patients aged 1-70 years who have certain types of relapsed or refractory blood cancers that express the CD19 protein[1]. Some key eligibility criteria include:
- Having a blood cancer that has come back (relapsed) or not responded to previous treatments (refractory)
- Having adequate organ function
- Having a life expectancy of at least 12 weeks
- Not having active central nervous system involvement by the cancer
- Not having had prior gene therapy treatment
- Not having certain active infections or other medical conditions that might interfere with the treatment
It’s important to note that there are additional specific criteria that doctors use to determine if a patient is eligible for the trial.
Safety and Efficacy Measures
The researchers will be closely monitoring several aspects of the treatment to assess its safety and effectiveness[1]. These include:
- Response rates to the treatment
- Overall survival and progression-free survival of patients
- How long it takes for blood cell counts to recover after treatment
- The need for additional treatments after CAR T-cell therapy
Potential Side Effects
As with any new treatment, there are potential side effects that the researchers will be carefully monitoring[1]. Some of the main side effects they’re watching for include:
- Cytokine Release Syndrome (CRS): A condition where the immune system becomes highly activated, potentially causing fever, low blood pressure, and other symptoms
- Neurotoxicity: Side effects that affect the nervous system, which could include confusion, seizures, or other neurological symptoms
- Prolonged cytopenia: A prolonged decrease in blood cell counts, which could increase the risk of infections or bleeding
- Infections: Including episodes of neutropenic fever (fever with a low white blood cell count)
The trial includes plans for managing these potential side effects, including the use of medications like tocilizumab and glucocorticoids if needed.
